Osteoclast Apoptosis: The Role of Fas in Vivo and in Vitro

Endocrinology

Volumn 144, Issue 12, 2003, Pages 5545-5555

  Wu, Xiaojun ^a   McKenna, Margaret A ^a   Feng, X U ^a   Nagy, Tim R ^b   McDonald, Jay M ^a,c  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 9; CYTOCHROME C; FAS ANTIBODY; FAS ANTIGEN;

AGED; ANIMAL CELL; APOPTOSIS; ARTICLE; BONE DENSITY; BONE MINERAL; CELL COUNT; CELL DIFFERENTIATION; CELL MATURATION; CELL SURVIVAL; CONTROLLED STUDY; FOWL; HUMAN; HUMAN CELL; IMMUNE SYSTEM; MACROPHAGE; MITOCHONDRION; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRABECULAR BONE; UPREGULATION;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; BONE DENSITY; BONE REMODELING; CELL DIFFERENTIATION; CELL LINEAGE; CHICKENS; HUMANS; IMMUNE SYSTEM; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, INBRED MRL LPR; MONOCYTES; OSTEOCLASTS; SIGNAL TRANSDUCTION;

EID: 0344394236     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2003-0296     Document Type: Article

References (64)

1. Manolagas SC 2000 Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21:115-137
2. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176
3. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T 1998 Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597-3602
4. Suda T, Takahashi N, Martin TJ 1992 Modulation of osteoclast differentiation. Endocr Rev 13:66-80
5. Yoshida H, Hayashi S, Kunisada T, Ogawa M, Nishikawa S, Okamura H, Sudo T, Shultz LD 1990 The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 345:442-444
6. Hofstetter W, Wetterwald A, Cecchini MC, Felix R, Fleisch H, Mueller C 1992 Detection of transcripts for the receptor for macrophage colony-stimulating factor, c-fms, in murine osteoclasts. Proc Natl Acad Sci USA 89:9637-9641
7. Hughes DE, Dai A, Tiffee JC, Li HH, Mundy GR, Boyce BF 1996 Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-β. Nat Med 2:1132-1136
8. Kameda T, Mano H, Yuasa T, Mori Y, Miyazawa K, Shiokawa M, Nakamaru Y, Hiroi E, Hiura K, Kameda A, Yang NN, Hakeda Y, Kumegawa M 1997 Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoclasts. J Exp Med 186:489-495
9. Arnett TR, Lindsay R, Kilb JM, Moonga BS, Spowage M, Dempster DW 1996 Selective toxic effects of tamoxifen on osteoclasts: comparison with the effects of oestrogen. J Endocrinol 149:503-508
10. Halasy-Nagy JM, Rodan GA, Reszka AA 2001 Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Bone 29:553-559
11. Boyce BF, Xing L, Jilka RL, Bellido T, Weinstein RS, Parfitt AM, Manolagas SC 2002 Apoptosis in bone cells. In: Bilezikian JP, Raisz LG, Rodan GA, eds. Principles of bone biology. 2nd ed. Vol 1. San Diego: Academic Press; 151-168
12. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F 1996 The Fas counter-attack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 184:1075-1082
13. Fulda S, Sieverts H, Friesen C, Herr I, Debatin KM 1997 The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 57:3823-3829
14. Nagata S 1999 Fas ligand-induced apoptosis. Annu Rev Genet 33:29-55
15. Nagafuji K, Shibuya T, Harada M, Mizuno S, Takenaka K, Miyamoto T, Okamura T, Gondo H, Niho Y 1995 Functional expression of Fas antigen (CD95) on hematopoietic progenitor cells. Blood 86:883-889
16. Wang XM, Yu SF, Yang ZP 2000 Apoptosis of osteoclast-like cells induced by alendronate is related to Fas gene expression. Chin J Dent Res 3:26-32
17. Andrews BS, Eisenberg RA, Theofilopoulos AN, Izui S, Wilson CB, McConahey PJ, Murphy ED, Roths JB, Dixon FJ 1978 Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J Exp Med 148:1198-1215
18. Roths JB, Murphy ED, Eicher EM 1984 A new mutation, gld, that produces lymphoproliferation and autoimmunity in C3H/HeJ mice. J Exp Med 159:1-20
19. Watanabe T, Sakai Y, Miyawaki S, Shimizu A, Koiwai O, Ohno K 1991 A molecular genetic linkage map of mouse chromosome 19, including the lpr, Ly-44, and Tdt genes. Biochem Genet 29:325-335
20. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S 1992 Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356:314-317
21. Adachi M, Watanabe-Fukunaga R, Nagata S 1993 Aberrant transcription caused by the insertion of an early transposable element in an intron of the Fas antigen gene of lpr mice. Proc Natl Acad Sci USA 90:1756-1760
22. Wu J, Zhou T, He J, Mountz JD 1993 Autoimmune disease in mice due to integration of an endogenous retrovirus in an apoptosis gene. J Exp Med 178:461-468
23. Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copeland NG, Suda T, Nagata S 1994 Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 76:969-976
24. Hahne M, Peitsch MC, Innier M, Schroter M, Lowin B, Rousseau M, Bron C, Renno T, French L, Tschopp J 1995 Characterization of the non-functional Fas ligand of gld mice. Int Immunol 7:1381-1386
25. McHugh KP, Hodivala-Dilke K, Zheng MH, Namba N, Lam J, Novack D, Feng X, Ross FP, Hynes RO, Teitelbaum SL 2000 Mice lacking β3 integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest 105: 433-440
26. Blair HC, Teitelbaum SL, Schimke PA, Konsek JD, Koziol CM, Schlesinger PH 1988 Receptor-mediated uptake of a mannose-6-phosphate bearing glycoprotein by isolated chicken osteoclasts. J Cell Physiol 137:476-482
27. Williams JP, Blair HC, McKenna MA, Jordan SE, McDonald JM 1996 Regulation of avian osteoclastic H+ -ATPase and bone resorption by tamoxifen and calmodulin antagonists. Effects independent of steroid receptors. J Biol Chem 271:12488-12495
28. Kameda T, Ishikawa H, Tsutsui T 1995 Detection and characterization of apoptosis in osteoclasts in vitro. Biochem Biophys Res Commun 207:753-760
29. Bridgham JT, Johnson AL 2001 Expression and regulation of Fas antigen and tumor necrosis factor receptor type I in hen granulosa cells. Biol Reprod 65:733-739
30. Nagy TR, Clair AL 2000 Precision and accuracy of dual-energy x-ray absorptiometry for determining in vivo body composition of mice. Obes Res 8:392-398
31. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595-610
32. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, Hase A, Seto Y, Nagata S 1991 The polypepride encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66:233-243
33. Deleted in proof
34. Trauth BC, Klas C, Peters AM, Matzku S, Moller P, Falk W, Debatin KM, Krammer PH 1989 Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245:301-305
35. Matsumoto K, Schleimer RP, Saito H, Iikura Y, Bochner BS 1995 Induction of apoptosis in human eosinophils by anti-Fas antibody treatment in vitro. Blood 86:1437-1443
36. Ibbotson KJ, Roodman GD, McManus LM, Mundy GR 1984 Identification and characterization of osteoclast-like cells and their progenitors in cultures of feline marrow mononuclear cells. J Cell Biol 99:471-480
37. Brown D, Breton S 1996 Mitochondria-rich, proton-secreting epithelial cells. J Exp Biol 199:2345-2358
38. Gottlieb RA 1999 Mitochondria: ignition chamber for apoptosis. Mol Genet Metab 68:227-231
39. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP, Wang X 1997 Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 275:1129-1132
40. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD 1997 The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 275:1132-1136
41. Weinstein RS, Manolagas SC 2000 Apoptosis and osteoporosis. Am J Med 108:153-164
42. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF 1995 Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10:1478-1487
43. Benford HL, McGowan NW, Helfrich MH, Nuttall ME, Rogers MJ 2001 Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 28:465-473
44. Brazil JJ, Gupta P 2002 Constitutive expression of the fas receptor and its ligand in adult human bone marrow: a regulatory feedback loop for the homeostatic control of hematopoiesis. Blood Cells Mol Dis 29:94-103
45. Kitaura H, Nagata N, Fujimura Y, Hotokezaka H, Yoshida N, Nakayama K 2002 Effect of IL-12 on TNF-α-mediated osteoclast formation in bone marrow cells: apoptosis mediated by Fas/Fas ligand interaction. J Immunol 169:4732-4738
46. Porter AG, Janicke RU 1999 Emerging roles of caspase-3 in apoptosis. Cell Death Differ 6:99-104
47. Straus SE, Sneller M, Lenardo MJ, Puck JM, Strober W 1999 An inherited disorder of lymphocyte apoptosis: the autoimmune lymphoproliferative syndrome. Ann Intern Med 130:591-601
48. Jackson CE, Fischer RE, Hsu AP, Anderson SM, Choi Y, Wang J, Dale JK, Fleisher TA, Middelton LA, Sneller MC, Lenardo MJ, Straus SE, Puck JM 1999 Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance. Am J Hum Genet 64:1002-1014
49. Wu J, Wilson J, He J, Xiang L, Schur PH, Mountz JD 1996 Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest 98:1107-1113
50. Kawakami A, Eguchi K, Matsuoka N, Tsuboi M, Koji T, Urayama S, Fujiyama K, Kiriyama T, Nakashima T, Nakane PK, Nagataki S 1997 Fas and Fas ligand interaction is necessary for human osteoblast apoptosis. J Bone Miner Res 12:1637-1646
51. Wu X, Pan G, McKenna MA, McDonald JM, RANKL regulates Fas expression during osteoclastogenesis. Program of the 25th Annual Meeting of the American Society for Bone and Mineral Research, Minneapolis, MN, 2003, p S234 (Abstract)
52. Katavic V, Lukic IK, Kovacic N, Grcevic D, Lorenzo JA, Marusic A 2003 Increased bone mass is a part of the generalized lymphoproliferative disorder phenotype in the mouse. J Immunol 170:1540-1547
53. Mor G, Sapi E, Abrahams VM, Rutherford T, Song J, Hao XY, Muzaffar S, Kohen F 2003 Interaction of the estrogen receptors with the Fas ligand promoter in human monocytes. J Immunol 170:114-122
54. Shinohara H, Yagita H, Ikawa Y, Oyazu N 2000 Fas drives cell cycle progression in glioma cells via extracellular signal-regulated kinase activation. Cancer Res 60:1766-1772
55. Grcevic D, Katavic V, Lukic IK, Kovacic N, Lorenzo JA, Marusic A 2001 Cellular and molecular interactions between immune system and bone. Croat Med J 42:384-392
56. Spector TD, Hall GM, McCloskey EV, Kanis JA 1993 Risk of vertebral fracture in women with rheumatoid arthritis. BMJ 306:558
57. Gough A, Sambrook P, Devlin J, Huissoon A, Njeh C, Robbins S, Nguyen T, Emery P 1998 Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis. J Rheumatol 25:1282-1289
58. Gough AK, Lilley J, Eyre S, Holder RL, Emery P 1994 Generalised bone loss in patients with early rheumatoid arthritis. Lancet 344:23-27
59. Goldring SR 1999 Osteoporosis and rheumatic diseases. In: Favus MJ, Christakos S, Robey PG, Goldring SR, Holick MF, Kaplan FS, Khosla S, Kleerekoper M, Langman CB, Lian JB, Shane E, Shoback DM, Stewart AF, Whyte MP, eds. Primer on the metabolic bone diseases and disorders of mineral metabolism. 4th ed. Philadelphia: Lippincott, Williams & Wilkins; 313-315
60. Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K, Takaoka A, Yokochi T, Oda H, Tanaka K, Nakamura K, Taniguchi T 2000 T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ. Nature 408:600-605
61. Matsue H, Kobayashi H, Hosokawa T, Akitaya T, Ohkawara A 1995 Keratinocytes constitutively express the Fas antigen that mediates apoptosis in IFN γ-treated cultured keratinocytes. Arch Dermatol Res 287:315-320
62. Ahn EY, Pan G, Vickers SM, McDonald JM 2002 IFN-γ upregulates apoptosis-related molecules and enhances Fas-mediated apoptosis in human cholangiocarcinoma. Int J Cancer 100:445-451
63. Spinozzi F, Agea E, Fizzotti M, Bassotti G, Russano A, Droetto S, Bistoni O, Grignani F, Bertotto A 1998 Role of T-helper type 2 cytokines in down-modulation of fas mRNA and receptor on the surface of activated CD4(+) T cells: molecular basis for the persistence of the allergic immune response. FASEB J 12:1747-1753
64. Wakisaka S, Suzuki N, Takeba Y, Shimoyama Y, Nagafuchi H, Takeno M, Saito N, Yokoe T, Kaneko A, Asai T, Sakane T 1998 Modulation by proinflammatory cytokines of Fas/Fas ligand-mediated apoptotic cell death of synovial cells in patients with rheumatoid arthritis (RA). Clin Exp Immunol 114:119-128